Tagamet HB first-year sales expected by SmithKline to top $100 mil..
This article was originally published in The Tan Sheet
Executive Summary
SMITHKLINE BEECHAM EXPECTS TAGAMET HB SALES TO EXCEED $100 MIL. in the first year. The new OTC heartburn drug, which began shipping to retailers on Aug. 14, had the largest first-day sales of any product in SmithKline's history, with 1 mil. cases of product delivered, the firm said. Based on the initial sell-in, the company expects Tagamet HB to "quickly" become the leading medication in the $1 bil. U.S. market for heartburn remedies.